Safety and efficacy of open-label subcutaneous ixekizumab treatment for 48 weeks in a phase II study in biologic-naive and TNF-IR patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 43, Issue 2, 2016, Pages 289-297

  Genovese, Mark C ^a,b,c   Braun, Daniel K ^a,b,c   Erickson, Janelle S ^a,b,c   Berclaz, Pierre Yves ^a,b,c   Banerjee, Subhashis ^a,b,c   Heffernan, Michael P ^a,b,c   Carlier, Hilde ^a,b,c  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Biologic Na ve; Ixekizumab; Rheumatoid arthritis; Tumor necrosis factor inadequate responder

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; IXEKIZUMAB; METHOTREXATE; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ACUTE PYELONEPHRITIS; ADULT; AMERICAN COLLEGE OF RHEUMATOLOGY 20; AMERICAN COLLEGE OF RHEUMATOLOGY 50; AMERICAN COLLEGE OF RHEUMATOLOGY 70; ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; BRONCHITIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DAS28; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FEMALE; FURUNCULOSIS; HUMAN; LEUKOCYTE COUNT; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MENINGITIS; MIDDLE AGED; MYCOBACTERIOSIS; MYCOSIS; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS INFECTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UROSEPSIS; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RETREATMENT; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84969404312     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140831     Document Type: Article

References (12)

1. McInnes IB. Cytokines. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR, eds. Kelley's textbook of rheumatology, 9th edition. Philadelphia: WB Saunders; 2009:367-77.
2. Chao CC, Chen SJ, Adamopoulos IE, Davis N, Hong K, Vu A, et al. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 2011;44:243-52.
3. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004;50:650-9.
4. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010;62:929-39.
5. Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheum 2014;66:1693-704.
6. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
7. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
8. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
9. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
10. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
11. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
12. Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, et al; GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21.